Literature DB >> 22959232

AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery.

Suzanne M Connolly, Diane R Baker, Brett M Coldiron, Michael J Fazio, Paul A Storrs, Allison T Vidimos, Mark J Zalla, Jerry D Brewer, Wendy Smith Begolka, Timothy G Berger, Michael Bigby, Jean L Bolognia, David G Brodland, Scott Collins, Terrence A Cronin, Mark V Dahl, Jane M Grant-Kels, C William Hanke, George J Hruza, William D James, Clifford Warren Lober, Elizabeth I McBurney, Scott A Norton, Randall K Roenigk, Ronald G Wheeland, Oliver J Wisco.   

Abstract

The appropriate use criteria process synthesizes evidence-based medicine, clinical practice experience, and expert judgment. The American Academy of Dermatology in collaboration with the American College of Mohs Surgery, the American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery has developed appropriate use criteria for 270 scenarios for which Mohs micrographic surgery (MMS) is frequently considered based on tumor and patient characteristics. This document reflects the rating of appropriateness of MMS for each of these clinical scenarios by a ratings panel in a process based on the appropriateness method developed by the RAND Corp (Santa Monica, CA)/University of California-Los Angeles (RAND/UCLA). At the conclusion of the rating process, consensus was reached for all 270 (100%) scenarios by the Ratings Panel, with 200 (74.07%) deemed as appropriate, 24 (8.89%) as uncertain, and 46 (17.04%) as inappropriate. For the 69 basal cell carcinoma scenarios, 53 were deemed appropriate, 6 uncertain, and 10 inappropriate. For the 143 squamous cell carcinoma scenarios, 102 were deemed appropriate, 7 uncertain, and 34 inappropriate. For the 12 lentigo maligna and melanoma in situ scenarios, 10 were deemed appropriate, 2 uncertain, and 0 inappropriate. For the 46 rare cutaneous malignancies scenarios, 35 were deemed appropriate, 9 uncertain, and 2 inappropriate. These appropriate use criteria have the potential to impact health care delivery, reimbursement policy, and physician decision making on patient selection for MMS, and aim to optimize the use of MMS for scenarios in which the expected clinical benefit is anticipated to be the greatest. In addition, recognition of those scenarios rated as uncertain facilitates an understanding of areas that would benefit from further research. Each clinical scenario identified in this document is crafted for the average patient and not the exception. Thus, the ultimate decision regarding the appropriateness of MMS should be determined by the expertise and clinical experience of the physician.
Copyright © 2012 American Academy of Dermatology, Inc. and the American Society for Dermatologic Surgery, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22959232     DOI: 10.1016/j.jaad.2012.06.009

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  58 in total

1.  Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2015 MauiDerm Meeting.

Authors:  Seemal R Desai; Ilona J Frieden; Joel M Gelfand; Whitney High; Arthur Kavanaugh; Ashfaq A Marghoob; David M Ozog; Ted Rosen; Linda Stein Gold; Bruce Strober; Neil Swanson; George Martin
Journal:  J Clin Aesthet Dermatol       Date:  2015-09

2.  Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2013 MauiDerm Meeting.

Authors:  Andrew Blauvelt; Marc Brown; Kenneth B Gordon; Arthur Kavanaugh; Craig T Leonardi; Eggert Stockfleth; Bruce Strober; Neil A Swanson; George Martin
Journal:  J Clin Aesthet Dermatol       Date:  2013-09

Review 3.  Research gaps in the management and prevention of cutaneous squamous cell carcinoma in organ transplant recipients.

Authors:  M Blomberg; S Y He; C Harwood; S T Arron; S Demehri; A Green; M M Asgari
Journal:  Br J Dermatol       Date:  2017-10-30       Impact factor: 9.302

4.  Variance of Basal Cell Carcinoma Subtype Reporting by Practice Setting.

Authors:  Deborah J Moon; Shauna Higgins; Shera Feinstein; Omeed Ahadiat; Adam Sutton; Ashley Wysong
Journal:  JAMA Dermatol       Date:  2019-07-01       Impact factor: 10.282

5.  A Protease-Activated Fluorescent Probe Allows Rapid Visualization of Keratinocyte Carcinoma during Excision.

Authors:  Ethan Walker; Yiqiao Liu; InYoung Kim; David L Wilson; James P Basilion; Daniel L Popkin; Mark Biro; Sukanya Raj Iyer; Harib Ezaldein; Jeffrey Scott; Miesha Merati; Rachel Mistur; Bo Zhou; Brian Straight; Joshua J Yim; Matthew Bogyo; Margaret Mann
Journal:  Cancer Res       Date:  2020-03-04       Impact factor: 12.701

6.  Rapid visualization of nonmelanoma skin cancer.

Authors:  Ethan Walker; Margaret Mann; Kord Honda; Allison Vidimos; Mark D Schluchter; Brian Straight; Matthew Bogyo; Daniel Popkin; James P Basilion
Journal:  J Am Acad Dermatol       Date:  2016-11-19       Impact factor: 11.527

7.  Line scanning, stage scanning confocal microscope (LSSSCM).

Authors:  Daniel S Gareau; James G Krueger; Jason E Hawkes; Samantha R Lish; Michael P Dietz; Alba Guembe Mülberger; Euphemia W Mu; Mary L Stevenson; Jesse M Lewin; Shane A Meehan; John A Carucci
Journal:  Biomed Opt Express       Date:  2017-07-24       Impact factor: 3.732

Review 8.  Mohs Micrographic Surgery: Development, Technique, and Applications in Cutaneous Malignancies.

Authors:  Eillen Luisa A Chen; Divya Srivastava; Rajiv I Nijhawan
Journal:  Semin Plast Surg       Date:  2018-05-14       Impact factor: 2.314

Review 9.  Advanced basal cell carcinoma.

Authors:  Uwe Wollina; Georgi Tchernev
Journal:  Wien Med Wochenschr       Date:  2013-04-16

10.  Evaluation of a Combined Reflectance Confocal Microscopy-Optical Coherence Tomography Device for Detection and Depth Assessment of Basal Cell Carcinoma.

Authors:  Aditi Sahu; Oriol Yélamos; Nicusor Iftimia; Miguel Cordova; Christi Alessi-Fox; Melissa Gill; Gopi Maguluri; Stephen W Dusza; Cristián Navarrete-Dechent; Salvador González; Anthony M Rossi; Ashfaq A Marghoob; Milind Rajadhyaksha; Chih-Shan J Chen
Journal:  JAMA Dermatol       Date:  2018-10-01       Impact factor: 10.282

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.